Replimune Group (NASDAQ: [[ticker:REPL]]) has appointed Jean Franchi to serve as chief financial officer, the same position she held most recently at Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]). Franchi’s experience also includes positions at Genzyme, Dimension Therapeutics, and Good Start Genetics. Woburn, MA-based Replimune is developing oncolytic immune-gene therapies to treat cancer.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
